- Home
- BYFC vs GOSS Comparison
BYFC vs GOSS Comparison
Compare BYFC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | GOSS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 97.5M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BYFC | GOSS |
|---|---|---|
| Price | $11.60 | $0.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 8.9K | ★ 27.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $184,000.00 | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | $165.72 | ★ N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $0.11 |
| 52 Week High | $12.31 | $3.87 |
Technical Indicators
Market Signals| Indicator | BYFC | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 43.68 |
| Support Level | $9.29 | $0.14 |
| Resistance Level | N/A | $0.20 |
| Average True Range (ATR) | 0.28 | 0.01 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 69.13 | 30.74 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).